{
  "id": "local_anaesthetics_pharmacology_001",
  "updatedAt": "2026-02-18T00:00:00Z",

  "domain": "pharmacology",
  "topicTagIds": ["local_anaesthetics", "pharmacology", "toxicity"],
  "caseId": null,
  "slotType": "any",
  "caseOrder": 0,

  "demographics": {
    "patientAgeGroup": "adult",
    "patientGender": "male"
  },

  "stem": "Dr. {{candidate_name}}, tell me about local anaesthetic drugs.",

  "prompts": [
    {
      "tier": "recall",
      "text": "What is the structure and classification of local anaesthetics?",
      "expectedKeyFacts": [
        "Consist of aromatic ring linked to amine group",
        "Classified by linkage: amides or esters",
        "Amides: lignocaine, bupivacaine, ropivacaine, levobupivacaine",
        "Esters: cocaine, procaine, amethocaine",
        "Amides metabolised by liver, esters by plasma cholinesterase",
        "Weak bases — mostly ionised at physiological pH"
      ],
      "timeBudgetSec": 60
    },
    {
      "tier": "mechanism",
      "text": "How do local anaesthetics work?",
      "expectedKeyFacts": [
        "Block voltage-gated sodium channels",
        "Prevent action potential propagation",
        "Non-ionised form crosses cell membrane",
        "Ionised form binds to intracellular part of sodium channel",
        "Preferentially block open/inactivated channels — use-dependent block",
        "Differential block: small myelinated fibres (B, Aδ) blocked before large fibres (Aα)",
        "Autonomic and pain fibres blocked before motor and proprioception"
      ],
      "timeBudgetSec": 90
    },
    {
      "tier": "application",
      "text": "What are the maximum safe doses of lignocaine and bupivacaine, and how do these change with adrenaline?",
      "expectedKeyFacts": [
        "Lignocaine: 3 mg/kg plain, 7 mg/kg with adrenaline",
        "Bupivacaine: 2 mg/kg plain or with adrenaline",
        "Adrenaline causes vasoconstriction — slows systemic absorption",
        "Prolongs duration of action",
        "Reduces peak plasma concentration",
        "Bupivacaine dose not increased with adrenaline due to cardiotoxicity risk",
        "Calculate dose based on ideal body weight in obesity"
      ],
      "timeBudgetSec": 90
    },
    {
      "tier": "synthesis",
      "text": "A patient develops signs of local anaesthetic toxicity. Describe the features and your management.",
      "expectedKeyFacts": [
        "Early CNS signs: perioral tingling, tinnitus, confusion, agitation",
        "Progressive CNS: seizures, loss of consciousness",
        "CVS toxicity: arrhythmias (VT/VF), myocardial depression, cardiovascular collapse",
        "Bupivacaine more cardiotoxic than lignocaine — binds tightly to cardiac sodium channels",
        "Management: stop injection, ABC, 100% oxygen",
        "Control seizures: benzodiazepines, small dose propofol/thiopentone",
        "Intralipid 20% — 1.5 mL/kg bolus then infusion",
        "Start CPR if cardiac arrest — may be prolonged",
        "Avoid vasopressin, beta-blockers, calcium channel blockers",
        "Alert cardiac bypass team — may need ECMO"
      ],
      "timeBudgetSec": 120
    },
    {
      "tier": "evaluation",
      "text": "Why is levobupivacaine or ropivacaine preferred over bupivacaine for major nerve blocks?",
      "expectedKeyFacts": [
        "Levobupivacaine is S-enantiomer of bupivacaine — less cardiotoxic",
        "Ropivacaine is pure S-enantiomer — less lipid-soluble, less CNS and CVS toxic",
        "Improved safety margin if accidental intravascular injection",
        "Ropivacaine causes less motor block — differential sensory block useful in labour",
        "Racemic bupivacaine R-enantiomer more cardiotoxic",
        "Accept that bupivacaine is cheaper and still widely used",
        "For major blocks with large doses, safety profile favours newer agents"
      ],
      "timeBudgetSec": 90
    }
  ],

  "rescuePrompt": "Perhaps you could tell me about the signs and symptoms of local anaesthetic toxicity — what would you see?",

  "keyFacts": [
    "Amides vs esters — different metabolism",
    "Block voltage-gated sodium channels",
    "Differential block — small fibres affected first",
    "Maximum doses: lignocaine 3 mg/kg (7 with adrenaline), bupivacaine 2 mg/kg",
    "Adrenaline reduces systemic absorption",
    "Toxicity: CNS excitation then depression, CVS collapse",
    "Bupivacaine highly cardiotoxic",
    "Intralipid 20% 1.5 mL/kg for toxicity",
    "Prolonged CPR may be needed",
    "Levobupivacaine and ropivacaine safer enantiomers",
    "pKa affects onset — closer to pH 7.4 = faster onset",
    "Protein binding affects duration"
  ],

  "scoringGuidance": {
    "pass": "Correct classification (amide/ester), explains sodium channel blockade, knows maximum doses and effect of adrenaline, describes features and management of LA toxicity including intralipid; stronger candidates explain enantiomers and differential block mechanism",
    "borderline": "Knows local anaesthetics block nerves and some drug names, vague on doses, mentions toxicity but unclear on management or intralipid protocol",
    "fail": "Cannot classify local anaesthetics, does not understand mechanism of action, unaware of maximum doses or toxicity features, no knowledge of intralipid rescue"
  },

  "author": "SimViva Team",
  "provenance": {
    "generatedBy": "Claude (Anthropic)",
    "generatedAt": "2026-02-18T20:55:00Z",
    "promptVersion": "v1.0.0",
    "sourceMaterial": ["AAGBI_LA_Toxicity_2010", "BJA_Local_Anaesthetics_2019"],
    "validation": {
      "reviewedBy": "",
      "reviewedAt": "",
      "status": "pending_review",
      "notes": "Awaiting clinical reviewer sign-off."
    }
  },
  "furtherReading": [
    "https://www.aagbi.org/sites/default/files/la_toxicity_2010_0.pdf"
  ],
  "isActive": true
}
